[{"id":"405369f8-6c34-4eaf-86cd-9b205b8bd8af","acronym":"ETCTN 10183","url":"https://clinicaltrials.gov/study/NCT03854474","created_at":"2021-01-18T19:01:24.885Z","updated_at":"2025-02-25T15:18:02.909Z","phase":"Phase 1/2","brief_title":"Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma","source_id_and_acronym":"NCT03854474 - ETCTN 10183","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" EZH2 mutation","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/18/2019","start_date":" 11/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-12"},{"id":"35a86a04-d158-4bfb-8750-bfb724605cdd","acronym":"P30CA016672","url":"https://clinicaltrials.gov/study/NCT03383575","created_at":"2021-01-18T16:41:48.451Z","updated_at":"2025-02-25T14:37:54.258Z","phase":"Phase 2","brief_title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","source_id_and_acronym":"NCT03383575 - P30CA016672","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-10"},{"id":"15a57807-96a4-44c8-8faf-02682afe4492","acronym":"VALYM","url":"https://clinicaltrials.gov/study/NCT04842877","created_at":"2021-04-13T13:30:33.989Z","updated_at":"2025-02-25T16:26:30.882Z","phase":"Phase 2","brief_title":"Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04842877 - VALYM","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" SLC1A5","pipe":" | ","alterations":" EZH2 mutation","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ezharmia (valemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 12/03/2024","primary_completion_date":" 12/03/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-24"},{"id":"ad50b74e-df77-4142-938b-467110fb4a75","acronym":"SYMPHONY-1","url":"https://clinicaltrials.gov/study/NCT04224493","created_at":"2023-06-02T17:05:31.313Z","updated_at":"2024-07-02T16:34:26.311Z","phase":"Phase 3","brief_title":"Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04224493 - SYMPHONY-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 612","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"2bbb09d4-a4c2-44c0-86f9-0f0a553fad4d","acronym":"Mandolin","url":"https://clinicaltrials.gov/study/NCT06068881","created_at":"2023-10-05T16:11:20.119Z","updated_at":"2024-07-02T16:34:59.499Z","phase":"Phase 2","brief_title":"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an \"EZH2 Gain-of-function\" Genetic Mutation","source_id_and_acronym":"NCT06068881 - Mandolin","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 09/28/2027","primary_completion_date":" 09/28/2027","study_txt":" Completion: 09/28/2027","study_completion_date":" 09/28/2027","last_update_posted":"2024-06-03"},{"id":"290f9c1c-d70d-4aad-827e-5424eb25383a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047993","created_at":"2021-01-17T17:15:53.781Z","updated_at":"2024-07-02T16:35:03.817Z","phase":"Phase 1/2","brief_title":"Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome","source_id_and_acronym":"NCT03047993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH1 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH1 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • telaglenastat (CB-839)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 03/16/2023","primary_completion_date":" 03/16/2023","study_txt":" Completion: 03/16/2023","study_completion_date":" 03/16/2023","last_update_posted":"2024-05-14"},{"id":"a42b730f-7cb0-4a7e-b9c9-5253a2b3eeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390737","created_at":"2022-05-12T19:53:40.351Z","updated_at":"2024-07-02T16:35:04.605Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Clinical Activity of HH2853","source_id_and_acronym":"NCT04390737","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" ARID1A • BAP1","pipe":" | ","alterations":" ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation","tags":["ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HH2853"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"e4a4b657-550e-4739-b71c-fff75613dfbe","acronym":"ETCTN 10500","url":"https://clinicaltrials.gov/study/NCT05627245","created_at":"2022-11-25T15:58:14.707Z","updated_at":"2024-07-02T16:35:09.644Z","phase":"Phase 1","brief_title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","source_id_and_acronym":"NCT05627245 - ETCTN 10500","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EZH2","pipe":" | ","alterations":" RAS wild-type • EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-15"},{"id":"d2fff3d6-ffea-4d7d-80f3-4801459b6711","acronym":"","url":"https://clinicaltrials.gov/study/NCT04659616","created_at":"2021-01-19T20:42:17.932Z","updated_at":"2024-07-02T16:35:10.819Z","phase":"Phase 1","brief_title":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT04659616","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation","tags":["TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-09"},{"id":"ec361a88-10be-462e-b8c7-8fa193d6a067","acronym":"","url":"https://clinicaltrials.gov/study/NCT03418038","created_at":"2021-01-18T16:51:47.082Z","updated_at":"2024-07-02T16:35:11.929Z","phase":"Phase 2","brief_title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT03418038","lead_sponsor":"Mayo Clinic","biomarkers":" IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation","tags":["IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-02"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"d92c2904-fae5-49ae-88c5-673b584f9118","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872543","created_at":"2022-03-16T22:55:47.285Z","updated_at":"2024-07-02T16:35:16.749Z","phase":"Phase 2","brief_title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","source_id_and_acronym":"NCT04872543","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SUZ12","pipe":" | ","alterations":" EZH2 mutation","tags":["SUZ12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/29/2021","start_date":" 04/29/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-01"},{"id":"544913f3-e7c0-4620-94d2-7b86fba5ea63","acronym":"","url":"https://clinicaltrials.gov/study/NCT05415098","created_at":"2022-06-10T12:58:54.863Z","updated_at":"2024-07-02T16:36:00.363Z","phase":"Phase 1","brief_title":"Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05415098","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" SMARCB1","pipe":" | ","alterations":" EZH2 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-5918"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2022-11-16"},{"id":"5642ea75-db05-4a40-a357-1d82d3c86f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03603951","created_at":"2021-01-18T17:43:03.285Z","updated_at":"2024-07-02T16:36:11.242Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms","source_id_and_acronym":"NCT03603951","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" EZH2 mutation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeprumetostat (SHR-2554)"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 02/14/2023","primary_completion_date":" 02/14/2023","study_txt":" Completion: 08/14/2023","study_completion_date":" 08/14/2023","last_update_posted":"2022-04-29"}]